Literature DB >> 2723544

Inhibition of acylcoenzyme A:cholesterol acyltransferase activity in CaCo-2 cells results in intracellular triglyceride accumulation.

N T Kam1, E Albright, S N Mathur, F J Field.   

Abstract

The activity of acylcoenzyme A:cholesterol acyltransferase (ACAT) in CaCo-2 cells was inhibited by the ACAT inhibitor, 58-035. The inhibitory effect of this acylamide was specific for cholesterol esterification catalyzed by ACAT; the rates of triglyceride, phospholipid, and cholesterol synthesis were not inhibited by this agent. Cholesteryl esters were depleted in CaCo-2 cells 24 hr after inhibition of ACAT activity, whereas the unesterified cholesterol content increased by 56% after 96 hr. Moreover, inhibiting ACAT activity with 58-035 resulted in a time-dependent 2.5-fold increase in intracellular triglycerides. This accumulation of triglycerides in CaCo-2 cells was associated with a 37% increase in triglyceride synthesis by 96 hr in the presence of 58-035. Triglyceride-rich lipoprotein secretion (d less than 1.006 g/ml) was not affected by inhibiting ACAT activity for up to 6 hr. However, triglyceride-rich lipoprotein secretion was significantly decreased in CaCo-2 cells that were preincubated with 58-035 for 24 to 96 hr. Lipoproteins of density less than 1.006 g/ml that were isolated from CaCo-2 cells incubated with the ACAT inhibitor were deficient in cholesteryl esters and triglycerides compared to lipoproteins isolated from control cells. The data suggest that triglycerides accumulate in CaCo-2 cells in which ACAT activity has been inhibited by 58-035. This accumulation of triglycerides is associated with a modest increase in triglyceride synthesis and a decrease in triglyceride secretion. Altering intracellular cholesterol pools by regulating ACAT activity in the gut could result in the decrease of triglyceride transport and/or the secretion of triglyceride-rich lipoprotein particles of abnormal composition.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2723544

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

1.  Effect of lovastatin on acyl-CoA: cholesterol O-acyltransferase (ACAT) activity and the basolateral-membrane secretion of newly synthesized lipids by CaCo-2 cells.

Authors:  N T Kam; E Albright; S Mathur; F J Field
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  Inhibition of acylcoenzyme A: cholesterol acyltransferase activity by PD128O42: effect on cholesterol metabolism and secretion in CaCo-2 cells.

Authors:  F J Field; E Albright; S Mathur
Journal:  Lipids       Date:  1991-01       Impact factor: 1.880

3.  Cholesterol: from feeding to gene regulation.

Authors:  C Martini; V Pallottini
Journal:  Genes Nutr       Date:  2007-09-27       Impact factor: 5.523

4.  Lysophosphatidylcholine increases the secretion of cholesteryl ester-poor triacylglycerol-rich lipoproteins by CaCo-2 cells.

Authors:  F J Field; E Born; H Chen; S Murthy; S N Mathur
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

5.  Antioxidant enzymes in the differentiated Caco-2 cell line.

Authors:  S S Baker; R D Baker
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

6.  The effects of simvastatin and cholestyramine, alone and in combination, on hepatic cholesterol metabolism in the male rat. off.

Authors:  J H Shand; D W West
Journal:  Lipids       Date:  1995-10       Impact factor: 1.880

7.  Iron absorption by intestinal epithelial cells: 1. CaCo2 cells cultivated in serum-free medium, on polyethyleneterephthalate microporous membranes, as an in vitro model.

Authors:  C Halleux; Y J Schneider
Journal:  In Vitro Cell Dev Biol       Date:  1991-04

8.  The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat.

Authors:  J H Shand; D W West
Journal:  Lipids       Date:  1994-11       Impact factor: 1.880

Review 9.  Intestinal lymphatic transport for drug delivery.

Authors:  Jaime A Yáñez; Stephen W J Wang; Ian W Knemeyer; Mark A Wirth; Kevin B Alton
Journal:  Adv Drug Deliv Rev       Date:  2011-06-13       Impact factor: 15.470

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.